TEL AVIV, Israel, March 5, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that Colin Foster, President and Chief Executive Officer of BioBlast Pharma, will provide a corporate overview at the 27th Annual ROTH Conference.
|ROTH Capital Markets Investor Conference|
|Time:||9:00-9:30am Pacific Time|
|Location:||Ritz Carlton, Dana Point, CA|
About BioBlast Pharma Ltd.
BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Founded in 2012, the company is rapidly building a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable genetic diseases. The BioBlast platforms are based on deep understanding of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.
CONTACT: U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 firstname.lastname@example.orgSource: BioBlast Pharma